Immunology
Tonix Pharmaceuticals to Present at BTIG Infectious Disease Day 2026, Highlighting Immunology Pipeline
Tonix Pharmaceuticals will participate in BTIG Infectious Disease Day 2026, showcasing its immunology programs including a Lyme disease prophylaxis candidate, underscoring its expansion beyond CNS treatments.
FIU Researchers Discover Method to Extend Immune Cell Lifespan, Potentially Boosting CAR-T Therapy Effectiveness
A new study from FIU researchers has found a way to extend the lifespan and efficacy of immune cells used in CAR-T therapy, which could improve treatment outcomes for blood cancers and potentially solid tumors.
Lifordi Immunotherapeutics Reports Positive Phase 1 Data for LFD-200 in Autoimmune Disease
Phase 1 data for LFD-200, a subcutaneous glucocorticoid antibody-drug conjugate, shows anti-inflammatory activity without systemic steroid toxicity, with patient dosing ongoing in rheumatoid arthritis.
New Study Reveals How Cancer Reprograms Immune Cells, Offering Hope for Immunotherapy Breakthrough
A study uncovering how cancer cells reprogram immune cells to support tumor growth could improve immunotherapy response rates, which currently fail in 80% of patients.
Immune Cell Surface Sugar Shedding Identified as Key Factor in Psoriasis Progression
New research reveals immune cells shed surface sugars before entering inflamed skin in psoriasis patients, potentially opening new treatment pathways for the chronic autoimmune condition.
GeoVax Vaccine Data Aligns With New IDSA Guidelines for Protecting Immunocompromised Patients
GeoVax's GEO-CM04S1 vaccine demonstrates robust T-cell responses and cross-variant durability in immunocompromised populations, addressing critical gaps identified in new IDSA guidelines that show current COVID-19 vaccines provide only moderate, short-lived protection for vulnerable patients.
Study Finds mRNA COVID Vaccine May Enhance Cancer Immunotherapy Effectiveness
New research presented at the European Society for Medical Oncology conference suggests mRNA coronavirus vaccines could potentially boost the effectiveness of cancer immunotherapy treatments.
GeoVax to Present COVID-19 Vaccine Data for Immunocompromised Patients at European Vaccine Congress
GeoVax Labs will present interim safety data and special-population insights for its GEO-CM04S1 COVID-19 vaccine at the World Vaccine Congress Europe 2025, highlighting progress in addressing vaccine needs for immunocompromised patients where current options remain insufficient.
Lund University Researchers Identify Mechanism Allowing Leukemia Cells to Evade Immune System
Researchers at Lund University have discovered why acute myeloid leukemia cells resist immunotherapy, potentially paving the way for more effective treatments for this aggressive blood cancer.
Study Reveals Common Nutrient May Enhance Cancer-Fighting Immune Cells
University of Chicago research indicates zeaxanthin, a nutrient found in common vegetables, could boost immune system effectiveness against cancer while complementary therapies like oncolytic viruses advance.
GeoVax's Multi-Antigen COVID-19 Vaccine Shows Superior Immune Response in CLL Patients Compared to mRNA Vaccines
GeoVax's GEO-CM04S1 vaccine demonstrated significantly better immune response in chronic lymphocytic leukemia patients than standard mRNA vaccines, addressing a critical unmet need in immunocompromised populations.
GeoVax's Multi-Antigen COVID-19 Vaccine Shows Strong Immune Response in Immunocompromised Patients
GeoVax Labs' GEO-CM04S1 vaccine demonstrates robust immunity in high-risk patients with blood cancers, potentially addressing a multi-billion dollar market where current vaccines have limited effectiveness.
GeoVax's Multi-Antigen COVID-19 Vaccine Shows Promise for Immunocompromised Patients
GeoVax Labs will present clinical data demonstrating that its GEO-CM04S1 vaccine generates cross-variant antibody and robust cellular immune responses in immunocompromised patients with hematologic malignancies, potentially addressing a critical gap in COVID-19 protection for vulnerable populations.
Nerve Damage Identified as Unexpected Cause of Cancer Immunotherapy Resistance
A multinational research team has discovered that cancer-induced nerve damage contributes to immunotherapy resistance, potentially opening new treatment avenues for patients.
Erica Ollmann Saphire Honored with 2025 San Diego Genius Award for Pioneering Immunology Research
Dr. Erica Ollmann Saphire, a leading figure in immunology research, is set to receive the 2025 San Diego Genius Award for her groundbreaking work on viral infections and immune system responses, highlighting the intersection of science and community enrichment.
New Genetic Discovery Enhances Cancer Immunotherapy Potential
A groundbreaking genetic discovery could significantly improve the effectiveness of cancer immunotherapy, offering new hope for patients with certain types of cancer.
Study Reveals Autoantibodies' Role in Enhancing Cancer Immunotherapy Efficacy
A recent study highlights the potential of autoantibodies in predicting the effectiveness of cancer immunotherapy, offering a new avenue for personalized treatment strategies.
Tonix Pharmaceuticals' TNX-1700 Shows Promise in Enhancing Immunotherapy for Gastric Cancer
Tonix Pharmaceuticals' preclinical data reveals TNX-1700's potential to improve immunotherapy outcomes in gastric cancer by targeting immunosuppressive neutrophils.
Soligenix Advances Treatment for Behçet’s Disease with New Clinical Trial
Soligenix Inc. has initiated a clinical trial for SGX945, a potential treatment for Behçet’s disease, a rare autoimmune disorder with limited treatment options, highlighting a significant step towards addressing the unmet needs of patients globally.
GeoVax's GEO-CM04S1 Shows Superior Immune Response in CLL Patients Compared to mRNA Vaccines
GeoVax Labs, Inc. reports that its GEO-CM04S1 vaccine has demonstrated superior T cell responses in chronic lymphocytic leukemia (CLL) patients compared to an authorized mRNA COVID-19 vaccine, highlighting potential advancements in protecting immunocompromised individuals.
GeoVax to Showcase Positive Immune Response Data for GEO-CM04S1 in CLL Patients at EHA 2025 Congress
GeoVax Labs, Inc. will present clinical data at the European Hematology Association 2025 Congress, demonstrating the superior cellular immune response of its GEO-CM04S1 vaccine in chronic lymphocytic leukemia patients compared to mRNA-based vaccines.
GeoVax's Multi-Antigen COVID-19 Vaccine Shows Promise Against Variants
GeoVax Labs, Inc. reports preclinical success of its multi-antigen COVID-19 vaccines, GEO-CM04S1 and GEO-CM02, in providing durable, cross-reactive immunity against SARS-CoV-2 variants, including Omicron XBB.1.5, highlighting the potential for broader protection without the need for frequent updates.
GeoVax to Present COVID-19 Vaccine Breakthroughs at Keystone Symposia
GeoVax Labs, Inc. will showcase data from two key studies at the Keystone Symposia, highlighting the cross-reactivity and broad-spectrum immunity of its COVID-19 vaccine candidates, marking a significant step forward in the fight against evolving SARS-CoV-2 variants.
GeoVax Reveals Promising Dual-Action Vaccine with Potential COVID-19 and Mpox Protection
A novel vaccine candidate, GEO-CM04S1, demonstrates robust immunogenicity against both COVID-19 and Mpox in immunocompromised and healthy populations, offering potential breakthrough in infectious disease prevention.
Study Reveals Pregnancy-Related Genes Contribute to Worse Lung Cancer Outcomes in Women
A new study from Memorial Sloan Kettering Cancer Center has uncovered how certain genes associated with pregnancy may negatively impact lung cancer survival rates in women, providing insights into potential future immune therapy developments.
Scinai Immunotherapeutics to Discuss Potential Breakthrough Treatment for Rare Skin Disorders
Scinai Immunotherapeutics will host a webinar to explore the therapeutic potential of PC111, a novel monoclonal antibody targeting rare skin conditions like Pemphigus Vulgaris and SJS/TEN, following its recent acquisition of Pincell.
GeoVax Reveals Promising Multi-Antigen COVID-19 Vaccine with Strong Immunocompromised Patient Response
GeoVax's experimental COVID-19 vaccine GEO-CM04S1 demonstrates exceptional immune responses across diverse populations, particularly in immunocompromised patients, potentially offering a more robust alternative to existing vaccines.
Soligenix Advances COVID-19 Vaccine Candidate CiVax Amid Ongoing Global Health Threat
Soligenix is developing CiVax, a heat-stable COVID-19 vaccine candidate, in response to persistent global health risks from the virus, with recent preclinical studies showing promising protection against multiple variants.
Portuguese Researchers Uncover Promising Immunotherapy Approach for Colorectal Cancer
A breakthrough discovery by Portuguese researchers reveals a new type of white blood cell with exceptional tumor identification capabilities, potentially revolutionizing colorectal cancer treatment through targeted immunotherapy.
Portuguese Researchers Uncover Promising White Blood Cell for Colorectal Cancer Immunotherapy
Researchers in Portugal have identified a novel white blood cell type with potent tumor cell identification capabilities, potentially revolutionizing immunotherapy approaches for colorectal cancer, the third most common cancer globally.